Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule

Xiaoyan Zhang, Lihong Chen, Jing Wu, Dongming Su, Wendell J. Lu, Mei-Tsuey Hwang, Guangrui Yang, Shuo Li, Minfen Wei, Linda Davis, Matthew D. Breyer, Youfei GuanAmerican 2005 · DOI

TL;DR

This study reveals that activating Liver X Receptors (LXRs) with the drug TO-901317 significantly increases the expression of stearoyl-CoA desaturase-1 (SCD1) in the kidney's proximal straight tubules. This finding is important because LXRs are key regulators of lipid metabolism, and SCD1 plays a crucial role in fatty acid synthesis, suggesting a novel mechanism by which LXRs influence kidney function and lipid homeostasis.

What Problem Does This Paper Address?

The kidney is a vital organ for lipid metabolism, and disruptions in this process, known as dyslipidemia, can accelerate kidney damage. Liver X Receptors (LXRs) are known intracellular sensors that control genes involved in lipid absorption, excretion, and cellular efflux. While LXRs are well-studied in the liver and other tissues, their specific role in kidney lipid metabolism and how they might influence kidney health, particularly in the context of dyslipidemia, remained largely unexplored. This paper aims to elucidate the impact of LXR activation on gene expression within the kidney, focusing on identifying specific genes and cellular locations that are affected.

Methods

The researchers employed a multi-pronged approach:

  • In Vivo Studies: C57 Bl/6 mice were treated with the LXR agonist TO-901317 or a vehicle control.
  • Gene Expression Profiling: Affymetrix GeneChip microarrays were used to comprehensively analyze changes in gene expression in the kidneys of treated versus control mice.
  • Northern Blot Analysis: This technique was used to confirm and quantify the changes in mRNA levels for specific genes, particularly SCD1 and SCD2.
  • Fatty Acid Analysis: Gas-liquid chromatography was used to analyze the fatty acid profiles in kidney lipids, specifically to assess changes in fatty acid desaturation.
  • In Situ Hybridization: This method allowed researchers to visualize the location of SCD1 mRNA within the kidney tissue.
  • Immunohistochemistry: This technique was used to detect and localize SCD1 protein expression in kidney tissue.
  • Double-Labeling Studies: Combining in situ hybridization with immunostaining for specific kidney tubule markers (aquaporin-2 and Tamm-Horsfall protein) helped pinpoint the exact cell types expressing SCD1.
  • In Vitro Studies: Cultured murine proximal tubule cells (MCT cells) were used to investigate the molecular mechanisms underlying LXR-mediated gene regulation.
  • Reporter Assays: Luciferase reporter assays were employed to study the transcriptional activity of the SCD1 promoter and the role of sterol regulatory element-binding protein-1c (SREBP1c).
  • Western Blot Analysis: This was used to detect the active form of SREBP1c in cultured cells.
  • Quantitative Real-Time PCR (qRT-PCR): Used to confirm mRNA expression levels in cultured cells.

Datasets

Not discussed in the paper. The study utilized Affymetrix GeneChip microarrays for global gene expression profiling in mouse kidneys.

Key Insights and Ideas

  • LXRs are active in the kidney: The study confirmed that both LXRα and LXRβ isoforms are expressed in mouse kidneys, suggesting they play a physiological role there.
  • SCD1 is a major LXR target in the kidney: The most dramatic effect of LXR activation was the significant upregulation of SCD1 gene expression. This points to SCD1 as a key player in how LXRs influence kidney lipid metabolism.
  • SCD1 is specifically localized to proximal straight tubules: Through detailed anatomical studies, the researchers found that SCD1 expression is concentrated in the proximal straight tubules, a critical segment for reabsorption and metabolic processing in the kidney. This specificity is important for understanding localized effects.
  • LXR activation alters kidney lipid composition: The increased SCD1 activity led to a higher ratio of monounsaturated to saturated fatty acids in kidney triglycerides, indicating a direct impact on the kidney's lipid profile.
  • SREBP1c acts as a mediator: The in vitro studies suggest that LXR activation upregulates SCD1 expression indirectly, likely through the transcription factor SREBP1c, which is itself a target of LXRs. This reveals a signaling cascade.

Key Results

  • Treatment with the LXR agonist TO-901317 resulted in the significant regulation of 51 transcripts in the mouse kidney.
  • SCD1 mRNA levels were markedly increased (approximately 5.4-fold by Northern blot) in TO-901317-treated mice compared to controls.
  • SCD2 mRNA levels were also increased (approximately 2.9-fold by Northern blot).
  • The fatty acid desaturation index in the kidney triglyceride fraction was significantly increased in TO-901317-treated mice.
  • In situ hybridization and immunohistochemistry confirmed that SCD1 mRNA and protein were predominantly expressed in the outer stripe of the outer medulla, specifically within proximal straight tubules.
  • In cultured proximal tubule cells, LXR activation significantly increased the active form of SREBP1c and enhanced SREBP1c promoter activity.
  • SREBP1c was shown to directly increase mouse SCD1 promoter activity in reporter assays.

Limitations and Future Work

  • Direct LXR binding to SCD1 promoter: The study found no direct LXRE (LXR response element) in the mouse SCD1 promoter region, suggesting that LXR does not directly bind to and regulate SCD1. This implies an indirect mechanism, which the paper explores through SREBP1c.
  • In vivo SREBP1c role: While in vitro studies strongly suggest SREBP1c mediates LXR's effect on SCD1, direct in vivo confirmation of this pathway in the kidney would strengthen the findings.
  • Functional consequences: The paper demonstrates the molecular and cellular changes but doesn't fully elucidate the long-term functional consequences of LXR-mediated SCD1 upregulation on overall kidney health or disease progression.
  • Broader LXR effects: While SCD1 was the most dramatically upregulated gene, the paper mentions other regulated genes. Further investigation into the roles of these other genes and their collective impact on kidney physiology would be valuable.
  • Clinical relevance: Future work could explore whether modulating LXR activity could be a therapeutic strategy for kidney diseases associated with dyslipidemia. Investigating the specific roles of LXRα and LXRβ in different kidney segments and their contributions to various renal pathologies would also be beneficial.

Summary updated

Abstract

Liver X receptors (LXRs), including LXRalpha and LXRbeta, are intracellular sterol sensors that regulate expression of genes controlling fatty acid and cholesterol absorption, excretion, catabolism, and cellular efflux. Because the kidney plays an important role in lipid metabolism and dyslipidemia accelerates renal damage, we investigated the effect of TO-901317, an LXR agonist, on the gene expression profile in mouse kidney. Treatment of C57 Bl/6 mice with TO-901317 (3 mg.kg(-1).day(-1)) for 3 days resulted in 51 transcripts that were significantly regulated in the kidney. Among them, the stearoyl-CoA desaturase-1 (SCD1) was upregulated most dramatically. Northern blot analysis revealed that SCD1 mRNA levels were markedly higher than that in control kidneys. Enhanced SCD1 expression by TO-901317 also resulted in increased fatty acid desaturation in the kidney. In control mice, constitutive renal SCD1 expression was low; however, TO-901317 treatment markedly increased SCD1 expression in the outer stripe of the outer medulla as assessed by both in situ hybridization and immunostain. Double-labeling studies further indicated that SCD1 mRNA was selectively expressed in proximal straight tubules negative for aquaporin-2 and Tamm-Horsfall protein. In vitro studies in cultured murine proximal tubule cells further demonstrated that LXR activation enhanced SCD1 transcription via increased sterol regulatory element binding protein-1. Taken together, these data suggest LXR activation of SCD1 expression may play an important role in regulating lipid metabolism and cell function in renal proximal straight tubules.
BibTeX
@inproceedings{zhang2005liver,
  author = {Xiaoyan Zhang and Xiaoyan Zhang and Lihong Chen and Jing Wu and Dongming Su and Wendell J. Lu and Mei-Tsuey Hwang and Guangrui Yang and Shuo Li and Minfen Wei and Linda Davis and Matthew D. Breyer and Youfei Guan},
  title = {{Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule}},
  booktitle = {American},
  year = {2005},
  doi = {10.1152/ajprenal.00131.2005},
}
Figure